MedTrace Logo

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

NCT02191540 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2014-07-23

No results posted yet for this study

Summary

Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion

Conditions

  • Malignant Pleural Effusion

Interventions

DRUG

Abnoba Viscum F 20mg

intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space

Sponsors & Collaborators

  • Abnoba Gmbh

    collaborator INDUSTRY

  • Abnoba Korea

    lead INDUSTRY

Principal Investigators

  • Kook Joo Na, MD · Chonnam National University Hospital

  • Friedemann Schad, MD · FORSCHUNGSINSTITUT HAVELHOHE

  • YongJik Lee, MD · Ulsan University Hospital

  • Yeong Dae Kim, MD · Busan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-01-31
Completion
2013-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191540 on ClinicalTrials.gov